Akero Therapeutics, Inc. (AKRO): Price and Financial Metrics
GET POWR RATINGS... FREE!
AKRO Stock Price Chart Interactive Chart >
AKRO Price/Volume Stats
| Current price | $39.26 | 52-week high | $39.74 |
| Prev. close | $38.31 | 52-week low | $7.52 |
| Day low | $38.04 | Volume | 669,398 |
| Day high | $39.74 | Avg. volume | 654,192 |
| 50-day MA | $18.63 | Dividend yield | N/A |
| 200-day MA | $15.16 | Market Cap | 1.48B |
Akero Therapeutics, Inc. (AKRO) Company Bio
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
Latest AKRO News From Around the Web
Below are the latest news stories about AKERO THERAPEUTICS INC that investors may wish to consider to help them evaluate AKRO as an investment opportunity.
Purple Innovation and Edgewise Therapeutics Stock See Action From Activist InvestorsColiseum Capital acquired almost half of the publicly traded shares of mattress firm Purple. OrbiMed Advisors increased its stake in pharmaceutical firm Edgewise Therapeutics. |
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesSOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its previously announced upsized underwritten public offering of 8,846,154 shares of its common stock at a public offering price of $26.00 per share, which includes the exercise in full by the underwriters of their option |
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common StockSOUTH SAN FRANCISCO, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an upsized underwritten public offering of 7,692,308 shares of its common stock at a public offering price of $26.00 per share. All of the shares in the offering are being offered by Akero Therapeutics. In addition, Akero |
Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & MoreRegulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week. |
Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. The biotech stock is extended and is not currently near a potential buy zone. |
AKRO Price Returns
| 1-mo | 193.86% |
| 3-mo | 243.48% |
| 6-mo | 183.06% |
| 1-year | 81.59% |
| 3-year | 112.79% |
| 5-year | N/A |
| YTD | 85.63% |
| 2021 | -18.02% |
| 2020 | 16.24% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...